Group 1 - The core viewpoint of the news highlights the strong performance of the innovative pharmaceutical sector, with the CSI Hong Kong Stock Connect Innovative Drug Index rising by 2.08% as of January 13, 2026, driven by significant gains in stocks such as Rongchang Bio (+9.38%), WuXi AppTec (+7.67%), and Tigermed (+7.66) [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing AI in drug development, AI-enabled pharmaceutical supply chains, surgical robots, and intelligent diagnostic systems as key development areas, with a goal to cultivate 2-3 ecosystem-leading enterprises by 2027 [1] - The integration of AI and healthcare is seen as a clear trend, with hardware companies represented by brain-computer interfaces and surgical robots expected to benefit from policy support and technological advancements [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Innovative Drug Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, accounting for a total of 71.36% of the index [2] - The Hong Kong Stock Connect Innovative Drug ETF managed by Harvest closely tracks the CSI Hong Kong Stock Connect Innovative Drug Index, which includes stocks involved in innovative drug research and development, as well as services for pharmaceutical companies [2] - Investors without stock accounts can access the opportunities in the Hong Kong innovative drug industry through the Hong Kong Stock Connect Innovative Drug ETF linked fund [2]

Group 1 - The core viewpoint of the news highlights the positive performance of the innovative drug sector in the stock market, with significant gains in individual stocks and ETFs [1][3] - The new national medical insurance drug catalog will be implemented on January 1, 2026, adding 114 new drugs, including 50 Class 1 new drugs, marking a record high in both quantity and proportion [2] - The commercial insurance catalog will include 19 high-value innovative drugs, addressing accessibility issues for high-value innovative treatments [2] Group 2 - The collaboration between domestic innovative drug companies and multinational corporations continues, with 49 outbound transactions totaling over $39 billion since October last year [3] - The market is entering a peak season for business development (BD) and data disclosures, coinciding with the JPM conference and the upcoming annual report cycle [3] - The Hong Kong Stock Connect Innovative Drug ETF (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.95% of the total weight [3]

Market Performance - The Hang Seng Technology Index increased by 0.38% and the Hang Seng Index rose by 1.01% [1] - The Hong Kong Technology ETF (159751) gained 1.38%, while the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 1.0% [1] Sector Performance - The life sciences tools and healthcare technology sectors showed the highest gains [1] - Conversely, the passenger airline and communication equipment sectors experienced the largest declines [1] Individual Stock Performance - BBSB International surged over 66% [1] - Zhaoyi Innovation rose by 39.75%, WuXi AppTec increased by 7.94%, CSPC Pharmaceutical Group gained 5.5%, Zijin Mining International rose by 5.49%, Ganfeng Lithium increased by 4.73%, WuXi Biologics rose by 4.52%, and Hansoh Pharmaceutical gained 4.13% [1] - Nanjing Panda Electronics fell by 5.47%, and Goldwind Technology dropped by 6.64% [1] - Ark Health gained 37.55%, and Haotian International Construction Investment rose by 17.86% [1]

Core Viewpoint - By December 2025, over 500 national key laboratories have completed restructuring into a new sequence, with nearly 110 "Double First-Class" universities participating in about 80% (nearly 400) of the national key laboratories [1][2]. Group 1: National Key Laboratories Overview - National key laboratories are scientific research and development institutions planned by the state to support the national laboratory system, focusing on major technological innovation areas related to national security and socio-economic development [2]. - The restructuring of the national key laboratory system was first proposed at the Central Economic Work Conference in 2018 and established as a component of national strategic scientific and technological forces in the revised "Science and Technology Progress Law" in 2021 [2]. Group 2: Participation of Universities - The leading or co-building universities for the laboratories are primarily "Double First-Class" universities, indicating a strong involvement of top-tier educational institutions in the research initiatives [1][2]. - Nearly 110 "Double First-Class" universities are involved in the establishment and support of approximately 400 national key laboratories [1][2]. Group 3: List of Key Laboratories - A variety of national key laboratories have been established across different fields, including: - Dark Matter Physics National Key Laboratory led by Shanghai Jiao Tong University [3] - Explosive Science and Safety Protection National Key Laboratory led by Beijing Institute of Technology [3] - Materials Chemistry Engineering National Key Laboratory led by Nanjing University of Technology [3] - The list includes laboratories focusing on diverse areas such as intelligent transportation, infectious disease research, and advanced manufacturing technologies [3][4][5].

Core Insights - The successful commercialization of a core drug is becoming a key pathway for some biotech companies to transition into biopharmaceutical enterprises. Madrigal Pharmaceuticals is gaining attention for its role transformation in 2025 with the approval of Rezdiffra, the first oral small molecule drug approved for treating metabolic dysfunction-associated steatotic liver disease (MASH) with fibrosis [1][2]. Financial Performance - Rezdiffra received FDA approval on March 1, 2024, and is projected to generate nearly $200 million in sales for the entire year of 2024, with expectations to exceed $1 billion in 2025. This sales growth is directly improving the company's financial situation, as Madrigal reported a loss of $406 million in the first three quarters of 2024, which narrowed to $206 million in the same period of 2025. Revenue surged from $76.81 million to $637 million during this timeframe [1][2]. Business Development Initiatives - Based on the cash flow and profit expectations from its core product, Madrigal is intensifying its business development efforts in 2025. The company entered into a licensing agreement with China’s CSPC Pharmaceutical Group for the oral GLP-1 small molecule agonist SYH2086, which includes an upfront payment of $120 million and a total deal value of up to $2.075 billion. Additionally, Madrigal announced an exclusive global licensing agreement with Pfizer for the oral DGAT-2 inhibitor Ervogastat, requiring a $50 million upfront payment and potential future milestone payments and royalties [2]. Strategic Focus - The introduction of the GLP-1 pipeline aims to explore the combination therapy of Rezdiffra with oral GLP-1 to balance the weight loss effects of GLP-1 with the anti-fibrotic and lipid-lowering effects of Rezdiffra, optimizing the efficacy and tolerability of MASH treatment. The strategy for the DGAT-2 inhibitor aligns with this approach [2]. Industry Context - Madrigal's transformation is not an isolated case. Companies like Argenx in Belgium and BeiGene in China have successfully transitioned from biotech to biopharmaceutical enterprises through their respective product successes. Argenx achieved this with its FcRn inhibitor efgartigimod in the treatment of myasthenia gravis, while BeiGene built a global R&D and commercialization network with its BTK inhibitor zanubrutinib [3].

中国生物制药（01177）盘中涨超4%，截至发稿，股价上涨3.50%，现报7.09港元，成交额4.39亿港元。 基于销售数据，美银证券微调其2026及2027年收入预测，目标价从9.4港元下调至8.3港元。此外，石药 集团因重点药品销售低迷，被维持"跑输大市"评级。 来源：新浪港股 报告显示，医院渠道销售额按年转降3.3%，零售渠道基本持平。中国生物制药产品表现分化，部分核 心产品销售额增长，但另一些显著下滑。 近日，美银证券发布报告指出，10月中国内地医药行业药品销售额按年下降3%，增速较9月大幅回落， 并重申对中国生物制药的"买入"评级。 ...

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen over 4%, currently trading at HKD 9.83 with a transaction volume of HKD 899 million, following the acceptance of its上市申请 for the Ploglitazone Metformin Sustained Release Tablets by the National Medical Products Administration of China [1] Group 1: Company Developments - CSPC Pharmaceutical Group is actively advancing the clinical development of a combination therapy consisting of Ploglitazone, Dapagliflozin, and Metformin to benefit more patients [1] - Ploglitazone is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that increases endogenous active GLP-1 levels, enhancing insulin secretion in response to glucose and improving hyperglycemia [1] - Metformin is a biguanide that reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases insulin sensitivity by enhancing peripheral glucose uptake and utilization [1]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has risen over 4%, currently trading at HKD 9.83 with a transaction volume of HKD 899 million, following the acceptance of its上市申请 for the Ploglitazone Metformin Sustained Release Tablets by the National Medical Products Administration of China [1] Group 1: Company Developments - CSPC Pharmaceutical Group is actively advancing the clinical development of a combination therapy consisting of Ploglitazone, Dapagliflozin, and Metformin, aiming to benefit more patients [1] - Ploglitazone is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that increases endogenous active GLP-1 levels, enhancing insulin secretion in response to glucose and improving hyperglycemia [1] - Metformin is a biguanide that reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases insulin sensitivity by enhancing peripheral glucose uptake and utilization [1]

Core Viewpoint - The Chinese innovative drug sector is experiencing significant growth, highlighted by the recent clinical advancements and strategic partnerships, indicating a positive long-term trend in the industry. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (南方, 159297) rose by 2.98%, with a turnover of 53.79 million yuan and a turnover rate of 3.2% [1] - Key stocks in the index, such as Rongchang Biopharmaceuticals, Sihuan Pharmaceutical, and Boan Biotechnology, saw substantial increases of 9.38%, 7.38%, and 6.71% respectively [1] Group 2: Clinical Developments - The GLP-1 class drug, Masitide, developed in China, achieved a milestone with two pivotal Phase III clinical studies published in the prestigious journal Nature on December 18, 2025, showcasing China's drug development capabilities [1] Group 3: Strategic Partnerships - Rongchang Biopharmaceuticals announced an exclusive licensing agreement with AbbVie for RC148, receiving an upfront payment of $650 million and potential milestone payments up to $4.95 billion, along with tiered royalties on net sales outside Greater China [1] Group 4: Industry Trends - Guosen Securities noted the explosive growth in business development (BD) transactions within the Chinese innovative drug industry, emphasizing that for many domestic innovative drugs, external licensing is just the starting point for global development [2] - The Hong Kong pharmaceutical sector has shown strong performance, particularly in the biotech field, reflecting heightened market interest in innovative drugs [2] Group 5: AI Integration - Eight departments jointly issued implementation opinions on "AI + Manufacturing," focusing on AI in drug development and medical supply chains, with a goal to cultivate 2-3 leading ecological enterprises by 2027 [2] - Century Securities highlighted the significant potential of AI in enhancing pharmaceutical manufacturing, particularly in drug discovery and intelligent diagnostics, which is expected to receive ongoing policy support and capital attention [2] Group 6: Index Composition - The index tracking the Hong Kong Stock Connect Innovative Drug sector includes major companies such as CSPC Pharmaceutical Group, BeiGene, and Innovent Biologics among its top ten weighted stocks [3]

Core Insights - The article highlights the net inflow and outflow of funds in the Hong Kong stock market, with Xiaomi Group, Tencent Holdings, and China Construction Bank leading in net inflows, while the Yingfu Fund, Hang Seng China Enterprises, and Southern Hang Seng Technology experienced the highest net outflows [1] Group 1: Net Inflows - Xiaomi Group-W (01810) recorded a net inflow of 1.07 billion, representing a 16.36% increase in its closing price [2] - Tencent Holdings (00700) saw a net inflow of 863 million, with a 7.49% increase in its closing price [2] - China Construction Bank (00939) had a net inflow of 699 million, with a significant 41.06% increase in its closing price [2] Group 2: Net Outflows - Yingfu Fund (02800) experienced the largest net outflow of 6.289 billion, reflecting a -31.44% change in its closing price [2] - Hang Seng China Enterprises (02828) had a net outflow of 2.880 billion, with a -17.89% change in its closing price [2] - Southern Hang Seng Technology (03033) faced a net outflow of 1.289 billion, showing a -11.37% change in its closing price [2] Group 3: Net Inflow Ratios - 361 Degrees (01361) led with a net inflow ratio of 74.40%, with a net inflow of 8.9117 million [3] - BRILLIANCE CHI (01114) followed with a net inflow ratio of 64.04%, amounting to a net inflow of 36.4910 million [3] - Qin Port Co. (03369) had a net inflow ratio of 61.05%, with a net inflow of 846,600 [3] Group 4: Net Outflow Ratios - Wisdom Hong Kong 100 (02825) had a net outflow ratio of -100.00%, with a net outflow of -18,200 [3] - Stone Pharmaceutical Group (02005) recorded a net outflow ratio of -68.86%, with a net outflow of -14.1501 million [3] - Dexion Shipping (02510) experienced a net outflow ratio of -53.53%, with a net outflow of -10.0204 million [3]